摘要
目的:探讨黄芪甲甙对乙型肝炎病毒(HBV)的体外抑制作用.方法:以HepG2.2.15细胞株为细胞模型,分别加入不同浓度的黄芪甲甙和拉米夫定,于培养第3,6和9日收集培养上清液.通过MTT法观察药物对HepG2.2.15细胞株的影响,采用ELISA法及荧光定量PCR法,分析药物对细胞培养上清液中HBsAg,HBeAg及HBVDNA含量的影响.结果:黄芪甲甙具有一定程度的抗HBV的作用.黄芪甲甙给药9d,其HBsAg的50%抑制浓度(IC50)为22.1mg/L,治疗指数(TI)为4.4;HBeAg的IC50为26.2mg/L,TI为3.72;细胞外HBVDNA的IC50为13.2mg/L,TI为7.4.拉米夫定也有抑制HBV的作用,但抑制作用较弱.结论:黄芪甲甙体外对HBV有抑制作用.
AIM： To study the inhibitory effect of astragaloside IV on hepatitis B virus （HBV） replication in vitro. METHODS： Different concentrations of astragaloside IV and lamivudine in DMEM were added to the wells with the monolayer growth of HepG2.2.15 cells and the supematant was collected at day 3, 6 and 9. The cytotoxic activity of drugs on HepG2.2. 15 cells was detected by means of MTr. The concentrations of HBsAg and HBeAg in the culture supematant were determined by enzymelinked immtmosorbent assay （ELISA） and the extracellular HBV DNA was measured by real-time PCR. RESULTS： When administrated for 9 d, astragaloside IV produced dose-dependent inhibition of HBsAg and HBeAg excreted by HepG2.2.15 cells, with a 50% inhibitory concentration （ IC50 ） of 22. 1 mg/L and 26.2 rag/L, respectively, and selectivity index （TI） was 4.4 and 3.72, respectively. Astragaloside IV reduced extracellular HBV DNA replication in HepG2.2. 15 cells, with IC50 of 13.2 mg/L and TI was 7.4. The inhibition rate of astragaloside IV against HBV DNA was higher than that of lamivudine 5 mg/L. CONCLUSION： Astragaloside IV has a dose-dependent inhibitory effect on replication of human HBV in vitro.
出处
《第四军医大学学报》
北大核心
2007年第24期2291-2293,共3页
Journal of the Fourth Military Medical University
